SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to community excitement around its real-world brand initiatives, including energy drinks, merchandise, and sponsored events, fostering strong community engagement and IRL presence. The community is actively discussing these initiatives, along with the project's expansion and potential for significant growth, expressing strong conviction and encouraging others to join. Discussions also include updates on holder counts and on-chain metrics, alongside continued building efforts.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community speculates on potential breakouts and considers it an undervalued cryptocurrency. Some view LTC as a strong buy under $100, citing its long-term adoption and recent privacy upgrades. Discussions also revolve around its relationship with Bitcoin's price movements and whether it signals a broader altcoin season.

Concordium is the Layer-1 blockchain built for a new era of digital trust. With mandatory, privacy-preserving identity verification built into its consensus layer, utilizing zero-knowledge proof technology. Concordium also enables Protocol-level tokens that eliminate smart contract risks by being issued directly at the consensus layer, with built-in features that provide the infrastructure for compliance-ready use cases. At its core is Smart Money - programmable, identity-embedded, and compliance-ready value that powers trusted interactions across Web3. Smart Money enables frictionless exchange, automation, and verifiable trust by design. Unlike conventional blockchains, Concordium integrates trust, accountability, and privacy into its architecture from the ground up  bridging traditional systems and Web3 to build a transparent, sustainable digital future. The name Concordium comes from the Latin concordia—meaning harmony and agreement—a reflection of its mission to build infrastructure that embeds trust, privacy, and compliance into every interaction.

Concordium

Concordium ($CCD) is trending as community members highlight its focus on privacy, compliance, and real-world utility, positioning it as a key infrastructure play for stablecoins and PayFi. Recent partnerships, including integration with bitcoin.com wallets, are also sparking increased interest and bullish sentiment. The community believes its unique approach to verifiable trust and on-chain identity is setting it up for significant growth.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending due to a significant sell-off following earnings, despite the company beating expectations; the community is actively debating whether this drop is an overreaction or a sign of deeper issues. Community members are also discussing the impact of AI on the company's future, as well as a recent analyst downgrade. Despite the negative sentiment, some investors view the dip as a buying opportunity, citing the company's strong fundamentals and growth potential.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is trending amid discussions about its potential for growth and recent partnerships, with community members pointing to a Nasdaq-listed company's planned investment in AVAX tokens as a catalyst. The community is actively debating entry points and speculating on short-term price movements. Some traders anticipate a broader altcoin season could further boost AVAX.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as community members discuss its recent price surge and potential for further growth, fueled by news around CaffeineAI and Motoko upgrades. Bullish investors believe ICP is undervalued and represents the future of a decentralized internet, while others caution about pullbacks and compare it to previous pump-and-dump cycles. Community members are actively discussing buying the dip and anticipating a continued run, potentially driven by AI and cloud-related narratives.

Monero

Monero is gaining attention as discussions around privacy in crypto intensify, with some community members touting XMR as the only true privacy coin with real-world usage. Despite underperforming Bitcoin recently, some analysts suggest a bullish chart pattern and expect a corrective bounce. Community members are actively discussing its potential to outperform other cryptocurrencies and its role in a future where privacy is paramount.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

$SWEAT is experiencing increased attention as users discuss its potential and unique model of rewarding users with crypto for physical activity. The community highlights its long-term potential, with some anticipating a significant rise and others emphasizing the benefits of staking. Despite some mixed opinions, many see value in its core concept and are accumulating coins, while monitoring for potential breakouts.

GigaCloud Technology, Inc. specializes in global end-to-end business-to-business (B2B) electronic commerce (e-commerce) for large parcel merchandise. Its B2B ecommerce platform, the “GigaCloud Marketplace” integrates everything from discovery, payments and logistics tools into one easy-to-use platform. The firm offers a comprehensive solution that transports products from the manufacturers warehouse to the end customers doorstep, all in one place. The company was founded by Lei Wu on August 29, 2006 and is headquartered in El Monte, CA.

GigaCloud Technology Inc - Ordinary Shares - Class A

GigaCloud Technology Inc

GigaCloud Technology ($GCT) is trending as investors discuss its low P/E ratio and growth potential despite mixed sentiment around tariffs and potential insider selling; the community awaits the upcoming earnings report with anticipation of a strong showing that could catalyze a price surge. A recent settlement regarding claims of misleading investors is also circulating, though some believe GCT's unique logistics model and expansion into Europe position it for long-term success.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is trending as the community discusses its recent partnership with Nvidia for autonomous driving technology and a collaboration with Uber, despite mixed sentiment regarding the company's financial health and leadership. Investors are weighing the potential of these deals against concerns about profitability and dilution. Bullish traders are hoping for a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now?

Does Spruce Biosciences, Inc. (SPRB) have what it takes to be a top stock pick for momentum investors? Let's find out.

Shares of Spruce Biosciences (SPRB) surged to a 19-month high of $240 in Tuesday morning trading, prompting two trading halts due to extreme volatility.Trading was halted at 9:32 a.m. ET and again at 9:48 a.m. ET, according to data from Nasdaq Trader, citing a ‘Volatility Trading Pause’.<a href="http://stocktwits.com/symbol/SPRB">SPRB’s stock</a> was up 74%, trading around $229 at the time of writing. It ranked among the top trending tickers on Stocktwits, with retail sentiment climbing higher within ‘extremely bullish’ territory amid ‘extremely high’ chatter – recording the highest levels of retail activity seen this year. Data also showed that the number of retail traders monitoring SPRB shares jumped 76% over the past day.<figure class="image"><img style="aspect-ratio:1259/133;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_101031_png_dc3a1a3a6c.webp" alt="Screenshot 2025-10-07 101031.png" width="1259" height="133"><figcaption>SPRB retail sentiment and message volume on October 7 as of 10:00 a.m. ET | Source: Stocktwits</figcaption></figure>The rally follows Spruce Biosciences’ shares jumping 1,378% to close at $130.4 on Monday after the U.S. Food and Drug Administration (FDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">granted</a> Breakthrough Therapy Designation to tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB).Martin Shkreli also&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-nearly-doubles-premarket-pharma-bro-martin-shkreli-sees-280-upside/ch6PEVhR3Wj">disclosed</a> his long position in Spruce and expressed a bullish outlook. In a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/1975241784369262649">post</a> on X, Shkreli said he believes the treatment “will be approved” and become “the new standard of care,” predicting that Spruce’s stock could rise to $500. Shkreli, a former hedge fund manager and pharmaceutical executive who&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.justice.gov/usao-edny/pr/martin-shkreli-sentenced-seven-years-imprisonment-multi-million-dollar-fraud-scheme">served time</a> for securities fraud, did not provide a timeline for the forecast.MPS IIIB is a rare, inherited lysosomal storage disease that causes a gradual decline in motor skills and cognition, as well as hyperactivity with aggressive behavior. CEO Javier Szwarcberg said on Monday that the company is preparing to submit an application for approval of the therapy in MPS IIIB in the first quarter of 2026.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bnb-token-surges-to-record-high-overtakes-xrp-as-third-largest-cryptocurrency/ch6PaXTR3Wy">BNB Token Surges To Record High, Overtakes XRP As Third-Largest Cryptocurrency</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of abstract numbers amid rising stock market prices. (Photo by SEAN GLADWELL/Getty Images)

SPRB Stock Hits 19-Month High Amid Trading Halts

The rally follows Spruce Biosciences’ shares jumping 1,378% to close at $130.4 on Monday.

Equity

The rally follows Spruce Biosciences’ shares jumping 1,378% to close at $130.4 on Monday.


Spruce Biosciences' stock&nbsp;leaped over 90% in early premarket trading on Tuesday, topping the Stocktwits trending list,&nbsp;hours after investor Martin Shkreli disclosed his long position on the stock and discussed his optimistic outlook.That's after SPRB stock gained a staggering 1,378% to $130.4 in Monday's session, following the company's announcement that it&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">received</a> the FDA's 'Breakthrough Therapy Designation' for its new therapy for a rare neurological disease.Spruce's tralesinidase alfa enzyme replacement therapy (TA-ERT) is designed to treat Sanfilippo syndrome type B (MPS IIIB), a rare, inherited lysosomal storage disease that causes a gradual decline in motor skills and cognition, as well as hyperactivity with aggressive behavior.Shkreli said in an&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/1975241784369262649">X post</a> early Tuesday he believes the said treatment "will be approved" and become "the new standard of care," forecasting that it would push Spruce's stock to $500.&nbsp;Shkreli, a former hedge fund manager and pharmaceutical executive who has served time in jail for securities fraud, did not provide a timeline."I was working on a presentation when the news was scooped. but this drug restores the abnormally high levels of heparan sulfate to normal. without this drug, patients will die at 18. with normal ranges of HS, they may live a normal life," he said in a follow-up post.CEO Javier Szwarcberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251006024469/en/Spruce-Biosciences-Receives-U.S.-FDA-Breakthrough-Therapy-Designation-for-Tralesinidase-Alfa-Enzyme-Replacement-Therapy-TA-ERT-in-Sanfilippo-Syndrome-Type-B-MPS-IIIB">said</a> on Monday that the company is preparing to submit an application for approval of the therapy in MPS IIIB in the first quarter of 2026. According to Spruce, Sanfilippo Syndrome Type B affects one in 200,000 people in the U.S.FDA's 'Breakthrough Therapy Designation' expedites the development and regulatory review of promising therapies for serious or life-threatening conditions, with intensive FDA guidance.Notably, Shkreli also recently&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-bets-against-opendoor-but-retail-traders-call-it-an-obvious-long-backed-by-eric-jackson/chw0M0bRdsE">revealed a short position</a> in Opendoor Technologies' shares, a widely watched meme stock.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Spruce Biosciences Stock Nearly Doubles Premarket: 'Pharma Bro' Martin Shkreli Sees 280% Upside

SPRB stock surged by over 1,300% on Monday after the biotech firm received the FDA's 'Breakthrough Therapy Designation' for its new therapy for a rare neurological disease.

Spruce Biosciences (SPRB) on Monday said that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B.Sanfilippo syndrome type B (MPS IIIB) is a rare, inherited lysosomal storage disease caused by a deficiency in the enzyme alpha-N-acetylglucosaminidase, leading to the accumulation of heparan sulfate in cells, particularly neurons. It causes progressive neurological symptoms like cognitive and developmental impairment, hyperactivity with aggressive and destructive behavior, delayed speech, hearing loss, and motor skill deficits.Tralesinidase Alfa Enzyme Replacement Therapy is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB. The Breakthrough Therapy Designation is designed to expedite the development and regulatory review of promising therapies for serious or life-threatening conditions. It enables intensive FDA guidance and eligibility for rolling submission and priority review.Shares of SPRB traded 314% higher at the time of writing on Monday. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SPRB">SPRB stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.CEO Javier Szwarcberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251006024469/en/Spruce-Biosciences-Receives-U.S.-FDA-Breakthrough-Therapy-Designation-for-Tralesinidase-Alfa-Enzyme-Replacement-Therapy-TA-ERT-in-Sanfilippo-Syndrome-Type-B-MPS-IIIB">said</a> that the company is preparing to submit an application for approval of the therapy in MPS IIIB in the first quarter of 2026. According to Spruce, Sanfilippo Syndrome Type B affects one in 200,000 people in the U.S.Currently, there are no FDA-approved therapies for the disease, which drastically brings down the life expectancy of individuals to 15-19 years of age.SPRB stock rose over 200% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-listed-nyxoah-shares-soar-on-first-genio-system-implants-in-patients-with-sleep-disorder/ch6R4LYR3g1">US-Listed Nyxoah Shares Soar On First Genio System Implants In Patients With Sleep Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did Spruce Biosciences Stock Quadruple Today?

The FDA’s Breakthrough Therapy Designation is designed to expedite the development and regulatory review of promising therapies for serious or life-threatening conditions.

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of +36.36% and +4.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of +65.83% and +14.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates

Illumina (ILMN) delivered earnings and revenue surprises of +16.67% and +1.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant...

Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant...

Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$127.00
Prev Close	$119.29
Open	$119.00
Dividend Yield	0.00%
50-Day Moving Average	$73.77
Beta	1.22
Avg. Volume	1.35M
PE Ratio	-1.48

52-Week High	$240.00
52-Week Low	$4.28
Market Capitalization	$135.34M
EPS (Annual)	-$96.39
Price to Book	5.43
Revenue Per Employee	$233,857.14
Enterprise Value/EBITDA	N/A

SPRB
Spruce Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SPRB News

SPRBSpruce Biosciences Inc